Transplante de microbiota fecal no SUS: uma análise de impacto orçamentário
DOI:
https://doi.org/10.34019/1982-8047.2026.v52.51592Keywords:
Fecal microbiota transplantation, Clostridium infections, Clostridioides difficile, Analysis of the budgetary impact of therapeutic advances, . Technology assessment biomedicalAbstract
Introduction: Recurrent Clostridioides difficile infection is a significant cause of healthcare-associated diarrhea and is closely linked to antimicrobial use, with substantial impact on morbidity and mortality. In Brazil, the treatment of recurrent infections faces considerable limitations, as fidaxomicin is not available in the country. Therefore, the objective of this study was to determine the cost of colonoscopy-guided transplantation using fresh feces for the Unified Health System and to conduct a budget impact analysis regarding the incorporation of this transplantation for the treatment of recurrent infection. Methods: A budget impact analysis was conducted, considering the incorporation of fecal microbiota transplantation into the Unified Health System compared to the current treatment in Brazil, which includes metronidazole and vancomycin. Data on disease epidemiology and healthcare resource consumption were utilized. To estimate the transplantation cost, the Microcosting method was adopted. All parameters in the analysis were subject to variation concerning the point estimate, based on a deterministic univariate sensitivity analysis. Results: Over five years, an estimated savings of R$ 27,084.72 was observed in the scenario incorporating transplantation. The results were sensitive to variations in the cost of injectable metronidazole, transplantation cost, and recurrence after transplantation. Conclusion: The budget impact analysis demonstrated that incorporating transplantation for patients with recurrent C. difficile infection into the Unified Health System is feasible and may result in cost savings, contributing to the sustainability of the healthcare system.
Downloads
References
1. Donskey CJ. Update on Clostridioides difficile Infection in Older Adults. Infect Dis Clin North Am. 2023; 37(1):87-102. DOI:10.1016/j.idc.2022.10.001.
2. Knight DR, Imwattana K, Collins DA, Lim SC, Hong S, Putsathit P, et al. Genomic epidemiology and transmission dynamics of recurrent Clostridioides difficile infection in Western Australia. Eur J Clin Microbiol Infect Dis. 2023; 42(5):607-19. DOI: 10.1007/s10096-023-04569-x.
3. Guery B, Galperine T, Barbut F. Clostridioides difficile: diagnosis and treatments. BMJ 2019; 366:l4609. DOI: 10.1136/bmj.l4609.
4. Braga DS, Oliveira DF, Lourenço NV, Carvalho GM, Rezende VMLR, Lourenço TV, et al. Incidence of healthcare-associated Clostridioides difficile infection in a quaternary referral university hospital in Brazil. Anaerobe. 2023; 79:102672. DOI: 10.1016/j.anaerobe.2022.102672.
5. Maestri AC, Raboni SM, Morales HMP, Ferrari LF, Tuon FFB, Losso A, et al. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil. Anaerobe. 2020; 64:102238. DOI: 10.1016/j.anaerobe.2020.102238.
6. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021; 73(5):e1029-44. DOI: 10.1093/cid/ciab549.
7. NICE (UK). Clostridioides difficile infection: antimicrobial prescribing. NICE guideline [Internet]. London: National Institute for Health and Care Excellence [Internet]; 2021 [citado em 2025 dez. 19]. Disponível em: www.nice.org.uk/guidance/ng199.
8. Souza GN, Porto MJ, Santos JP, Freitas AL, Carvalho PP. Perfil das prescrições de antimicrobianos de uso restrito em uma Unidade de Terapia Intensiva. Res Soc Dev. 2021; 10(8):e15710816565. DOI: 10.33448/rsd-v10i8.16565.
9. Knudsen MJS, Rubin IMC, Petersen AM. The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection – A Systematic Review. Drug Healthc Patient Saf. 2023; 15:63-71. DOI: 10.2147/dhps.s348501.
10. Alves JDF, Yamaguti A, de Mendonça JS, Gamba CM, Fonseca CL, Paraskevopoulos DKS, et al. Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality. Antibiotics (Basel). 2022; 11(9):1162. DOI: 10.3390/antibiotics11091162.
11. Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med. 2020; 52(1-2):12-20. DOI: 10.1080/07853890.2019.1701703.
12. Trindade CNR, Domingues RMCP, Ferreira EO. The epidemiology of Clostridioides difficile infection in Brazil: A systematic review covering thirty years. Anaerobe. 2019; 58:13-21. DOI: 10.1016/j.anaerobe.2019.03.002.
13. Prefeitura de São Paulo (BR), Secretaria Municipal da Saúde. Prevenção contra as infecções relacionadas à assistência à saúde (IRAS) causadas por C. difficile [Internet]. São Paulo: Secretaria municipal de saúde; 2023 [citado em 2025 dez. 19]. Disponível em: https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/Notat%C3%A9cnica.pdf.
14. de Albuquerque Terra DA, Vilela EG, Silva ROS, Leão LA, Lima KS, Kuijper EJ, et al. Experience of the first Brazilian fecal microbiota transplantation center in treating recurrent Clostridioides difficile infection. Microb Health Dis. 2022; 4:e806. DOI: 10.26355/mhd_202212_806.
15. Tang G, Yin W, Liu W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis? Diagn Microbiol Infect Dis. 2017; 88(4):322-9. DOI: 10.1016/j.diagmicrobio.2017.05.007.
16. Ministério da Saúde (BR). Diretrizes Metodológicas: Análise de Impacto Orçamentário: Manual para o Sistema de Saúde do Brasil [Internet]. Brasília: Ministério da Saúde; 2012 [citado em 2025 dez. 19]. Disponível em: https://www.gov.br/conitec/pt-br/midias/artigos_publicacoes/diretrizes/diretrizes_metodologicas_analise_impacto-1.pdf/@@display-file/file.
17. Tariq R, Hayat M, Pardi D, Khanna S. Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2021;40(7):1383-92. DOI: 10.1007/s10096-021-04163-z.
18. Aby ES, Vaughn BP, Enns EA, Rajasingham R. Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection. Clin Infect Dis. 2022; 75(9):1602-9. DOI: 10.1093/cid/ciac207.
19. Lodise T, Guo A, Yang M, Cook EE, Song W, Yang D, et al. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US. Adv Ther. 2023; 40(6):2801-2819. DOI: 10.1007/s12325-023-02506-0.
20. World Health Organization. 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis [Internet]. Geneva: World Health Organization; 2024 [citado em 2025 dezembro.19]. Disponível em: https://iris.who.int/bitstream/handle/10665/376944/9789240094000-eng.pdf?sequence=1.
21. Presidência da República (BR). Decreto nº 11.715, de 26 de setembro de 2023: Institui a Estratégia Nacional para o Desenvolvimento do Complexo Econômico-Industrial da Saúde [Internet]. Brasília: Presidência da República; 2023 [citado em 2025 dez. 19]. Disponível em: https://www.planalto.gov.br/ccivil_03/_ato2023-2026/2023/decreto/d11715.htm#:~:text=DECRETO.
22. Brazier A, Merriam S, Halpern D. BSAC Vanguard Series: Behavioural science and antimicrobial resistance. J Antimicrob Chemother. 2022; 77(7):1793-5. DOI: 10.1093/jac/dkac087.
23. Sakata RAP, Silva RC, Gales AC, Cuba GT, Pignatari ACC, Kiffer CRV. Broad-spectrum antimicrobial consumption trends and correlation with bacterial infections and antimicrobial resistance over 5 years. J Glob Antimicrob Resist. 2022; 28:115-9. DOI: 10.1016/j.jgar.2021.10.031.
24. Upadhayay A, Ling J, Pal D, Xie Y, Ping FF, Kumar A. Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat. Drug Resist Updat. 2023; 66:100890. DOI: 10.1016/j.drup.2022.100890.
25. Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019; 68(12):2111-21. DOI: 10.1136/gutjnl-2019-319548.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Tatiane Garcia do Carmo Flausino, Elene Paltrinieri Nardi, Bárbara Martins Lima, Fábio Ricardo Carrasco, Gerhard da Paz Lauterbach, Rosely Moralez de Figueiredo, Daniela Oliveira de Melo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Cessão de Primeira Publicação à HU Revista
Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.
![](<p style="text-align:center;"> <a href="https://www.instagram.com/hurevista/" target="_blank"> <img src="https://periodicos.ufjf.br/public/site/images/hurevista/instagram.png" alt="Instagram da HU Revista" width="80"> </a> </p>)
